{"id":4767,"date":"2012-05-25T14:31:49","date_gmt":"2012-05-25T18:31:49","guid":{"rendered":"https:\/\/www.braintumour.ca\/research_recipients\/dr-fortin-research-grant-2012\/"},"modified":"2020-05-20T19:07:23","modified_gmt":"2020-05-20T23:07:23","slug":"dr-fortin-research-grant-2012","status":"publish","type":"research_recipients","link":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/","title":{"rendered":"Dr. Fortin – Subvention de recherche 2012"},"content":{"rendered":"

Dr. David Fortin, Universite de Sherbrooke, Sherbrooke, Quebec<\/p>\n

Project Title: \u00ab\u00a0Characterization of the chemoresistance profiles of malignant gliomas – A step towards individualized treatments\u00a0\u00bb<\/h5>\n

What does the title mean?<\/h3>\n

This research focuses on the cells responsible for blocking treatment to the brain, specifically multi-drug resistant glioblastoma multiforme<\/p>\n

Project Summary:<\/h3>\n

\"DrGlioblastoma multiforme (GBM) is the most frequent primary brain tumour. The incurability of this disease can partially be explained a chemoresistance phenomenon.<\/p>\n

ABC transporter proteins are pumps expressed by glial cancer cells and by endothelial cell at the blood-brain barrier and blood-tumour barrier (BTB). In non-pathological conditions they protect the brain from drugs by insuring their exclusion from the brain, by pumping drugs back in the blood. However, these pumps are often overexpressed in cancer cells and give rise to chemoresistance to multiple anti-cancer drugs.<\/p>\n

Research efforts to find specific inhibitors of theses transporters are currently in progress. Four members of this family of proteins have been identified to be express in malignant gliomas: MDR1, MRP1, MRP3, BCRP. Since the response to treatment is highly heterogeneous in GBM patients the search for novel biomarkers is crucial. The detailed characterization of the expression profile of ABC transporters could predict GBM progression and to allow the administration of a personalized treatment.<\/p>\n

The aim of our research project is to characterize in glial cancer cells and BTB endothelial cells, the expression profile of four ABC transporters responsible for the drug delivery impediment to the brain and for the multidrug resistance in GBM patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dr. David Fortin, Universite de Sherbrooke. Project: \u00ab\u00a0Characterization of the chemoresistance profiles of malignant gliomas – A step towards individualized treatments\u00a0\u00bb<\/p>\n","protected":false},"featured_media":2229,"menu_order":0,"template":"","research_recipient_type":[285],"class_list":["post-4767","research_recipients","type-research_recipients","status-publish","has-post-thumbnail","hentry","research_recipient_type-grant-fr"],"acf":[],"yoast_head":"\nDr. Fortin - Subvention de recherche 2012 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales<\/title>\n<meta name=\"description\" content=\"Dr. David Fortin, Universite de Sherbrooke. Project: "Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments"\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Fortin - Subvention de recherche 2012\" \/>\n<meta property=\"og:description\" content=\"Dr. David Fortin, Universite de Sherbrooke. Project: "Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation canadienne des tumeurs c\u00e9r\u00e9brales\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-20T23:07:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2100\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/\",\"url\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/\",\"name\":\"Dr. Fortin - Subvention de recherche 2012 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales\",\"isPartOf\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg\",\"datePublished\":\"2012-05-25T18:31:49+00:00\",\"dateModified\":\"2020-05-20T23:07:23+00:00\",\"description\":\"Dr. David Fortin, Universite de Sherbrooke. Project: \\\"Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments\\\"\",\"breadcrumb\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage\",\"url\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg\",\"contentUrl\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg\",\"width\":2100,\"height\":1500,\"caption\":\"Dr Fortin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.braintumour.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Recipients\",\"item\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Dr. Fortin – Subvention de recherche 2012\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/#website\",\"url\":\"https:\/\/www.braintumour.ca\/fr\/\",\"name\":\"Fondation canadienne des tumeurs c\u00e9r\u00e9brales\",\"description\":\"Notre mission est de venir en aide \u00e0 toutes les personnes touch\u00e9es par une tumeur c\u00e9r\u00e9brale au Canada par le biais de nos programmes d\u2019information, de soutien, d\u2019\u00e9ducation et de recherche.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.braintumour.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dr. Fortin - Subvention de recherche 2012 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales","description":"Dr. David Fortin, Universite de Sherbrooke. Project: \"Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/","og_locale":"fr_CA","og_type":"article","og_title":"Dr. Fortin - Subvention de recherche 2012","og_description":"Dr. David Fortin, Universite de Sherbrooke. Project: \"Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments\"","og_url":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/","og_site_name":"Fondation canadienne des tumeurs c\u00e9r\u00e9brales","article_modified_time":"2020-05-20T23:07:23+00:00","og_image":[{"width":2100,"height":1500,"url":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/","url":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/","name":"Dr. Fortin - Subvention de recherche 2012 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales","isPartOf":{"@id":"https:\/\/www.braintumour.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage"},"image":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage"},"thumbnailUrl":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg","datePublished":"2012-05-25T18:31:49+00:00","dateModified":"2020-05-20T23:07:23+00:00","description":"Dr. David Fortin, Universite de Sherbrooke. Project: \"Characterization of the chemoresistance profiles of malignant gliomas - A step towards individualized treatments\"","breadcrumb":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#primaryimage","url":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg","contentUrl":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/David-Fortin.jpg","width":2100,"height":1500,"caption":"Dr Fortin"},{"@type":"BreadcrumbList","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-fortin-research-grant-2012\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.braintumour.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Research Recipients","item":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/"},{"@type":"ListItem","position":3,"name":"Dr. Fortin – Subvention de recherche 2012"}]},{"@type":"WebSite","@id":"https:\/\/www.braintumour.ca\/fr\/#website","url":"https:\/\/www.braintumour.ca\/fr\/","name":"Fondation canadienne des tumeurs c\u00e9r\u00e9brales","description":"Notre mission est de venir en aide \u00e0 toutes les personnes touch\u00e9es par une tumeur c\u00e9r\u00e9brale au Canada par le biais de nos programmes d\u2019information, de soutien, d\u2019\u00e9ducation et de recherche.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.braintumour.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"}]}},"_links":{"self":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipients\/4767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipients"}],"about":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/types\/research_recipients"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/media\/2229"}],"wp:attachment":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/media?parent=4767"}],"wp:term":[{"taxonomy":"research_recipient_type","embeddable":true,"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipient_type?post=4767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}